Use of magnetic resonance imaging for evaluation of therapeutic response in breast cancer-related lymphedema: A systematic review

 

 Permissions and Reprints

Breast cancer treatment-related lymphedema (BCRL) is a common comorbidity in breast cancer survivors. Although magnetic resonance imaging (MRI) is widely used to evaluate therapeutic response of patients with various medical conditions, it is not routinely used to evaluate lymphedema patients. We conducted a systematic review of the literature to identify studies on the use of MRI to evaluate therapy for BCRL. We hypothesized that MRI could provide information otherwise not possible through other examinations. On October 21, 2019, we conducted a systematic review on the PubMed/MEDLINE and Scopus databases, without time frame or language limitations, to identify studies on the use of MRI to evaluate therapy for BCRL. We excluded studies that investigated other applications of MRI, such as lymphedema diagnosis and surgical planning. Of 63 potential articles identified with the search, three case series fulfilled the eligibility criteria. In total, 53 patients with BCRL were included and quantitatively evaluated with MRI before and after manual lymphatic drainage. Authors used MRI or MR lymphagiography to investigate factors such as lymphatic vessel cross-sectional area, tissue water relaxation time (T₂), and chemical exchange saturation transfer. The only study that compared MRI measurement with standard examinations reported that MRI added information to the therapy evaluation. MRI seems to be a promising tool for quantitative measurement of therapeutic response in patients with BCRL. However, the identified studies focused on only manual lymphatic drainage and were limited by the small numbers of patients. More studies are necessary to shed light on the topic.

This study was supported in part by the Mayo Clinic Center for Individualized Medicine, and the Plastic Surgery Foundation.

Publication History

Received: 22 January 2020

Accepted: 18 June 2020

Article published online:
25 March 2022

© 2020. The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonCommercial License, permitting unrestricted noncommercial use, distribution, and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes. (https://creativecommons.org/licenses/by-nc/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• REFERENCES

• 1 Newman B, Lose F, Kedda MA. et al. Possible genetic predisposition to lymphedema after breast cancer. Lymphat Res Biol 2012; 10: 2-13
  CrossrefPubMedGoogle Scholar
• 2 Gallagher K, Marulanda K, Gray S. Surgical intervention for lymphedema. Surg Oncol Clin N Am 2018; 27: 195-215
  CrossrefPubMedGoogle Scholar
• 3 Weiss M, Baumeister RG, Frick A. et al. Lymphedema of the upper limb: evaluation of the functional outcome by dynamic imaging of lymph kinetics after autologous lymph vessel transplantation. Clin Nucl Med 2015; 40: e117-23
  CrossrefPubMedGoogle Scholar
• 4 Cormier JN, Askew RL, Mungovan KS. et al. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer 2010; 116: 5138-49
  CrossrefPubMedGoogle Scholar
• 5 DiSipio T, Rye S, Newman B. et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 2013; 14: 500-15
  CrossrefPubMedGoogle Scholar
• 6 Ozcinar B, Guler SA, Kocaman N. et al. Breast cancer related lymphedema in patients with different loco-regional treatments. Breast 2012; 21: 361-5
  CrossrefPubMedGoogle Scholar
• 7 McLaughlin SA, Wright MJ, Morris KT. et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 2008; 26: 5213-9
  CrossrefPubMedGoogle Scholar
• 8 Donahue PM, Crescenzi R, Scott AO. et al. Bilateral changes in deep tissue environment after manual lymphatic drainage in patients with breast cancer treatment-related lymphedema. Lymphat Res Biol 2017; 15: 45-56
  CrossrefPubMedGoogle Scholar
• 9 Kim L, Jeon JY, Sung IY. et al. Prediction of treatment outcome with bioimpedance measurements in breast cancer related lymphedema patients. Ann Rehabil Med 2011; 35: 687-93
  CrossrefPubMedGoogle Scholar
• 10 Szuba A, Strauss W, Sirsikar SP. et al. Quantitative radionuclide lymphoscintigraphy predicts outcome of manual lymphatic therapy in breast cancer-related lymphedema of the upper extremity. Nucl Med Commun 2002; 23: 1171-5
  CrossrefPubMedGoogle Scholar
• 11 Armer JM. The problem of post-breast cancer lymphedema: impact and measurement issues. Cancer Invest 2005; 23: 76-83
  CrossrefPubMedGoogle Scholar
• 12 Crescenzi R, Donahue PMC, Hartley KG. et al. Lymphedema evaluation using noninvasive 3T MR lymphangiography. J Magn Reson Imaging 2017; 46: 1349-60
  CrossrefPubMedGoogle Scholar
• 13 Crescenzi R, Donahue PMC, Mahany H. et al. CEST MRI quantification procedures for breast cancer treatment-related lymphedema therapy evaluation. Magn Reson Med 2020; 83: 1760-73
  CrossrefPubMedGoogle Scholar
• 14 Dayan JH, Ly CL, Kataru RP. et al. Lymphedema: pathogenesis and novel therapies. Annu Rev Med 2018; 69: 263-76
  CrossrefPubMedGoogle Scholar